亚宝药业集团股份有限公司2025年第三季度报告

Core Points - The company guarantees the authenticity, accuracy, and completeness of the quarterly report, and assumes legal responsibility for any false records or misleading statements [2][8][17] Financial Data - The third-quarter financial statements are unaudited, covering the period from the beginning to the end of the quarter [3][8] - The report includes significant non-recurring gains and losses, but specific amounts are not detailed in the provided documents [4] Shareholder Information - As of the end of the reporting period, the company has a total of 700,000,046 shares, with 6,000,000 shares (0.86%) held in a repurchase account [6] Board Meeting Resolutions - The company's board of directors approved the third-quarter report with unanimous support [8][11] - The board also approved revisions to the company's information disclosure system and management systems for shares held by directors and senior management [11][12][14]